Skip to Main Content

Paper Details

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance.
Vasc Health Risk Manag
8
2022
LDL-C, PCSK9, Proprotein convertase subtilisin/kexin type 9, atherosclerotic cardiovascular disease, cholesterol, low-density lipoprotein cholesterol
Author NameAffiliation
Xiaoming JiaBaylor College of Medicine
Mahmoud Al RifaiBaylor College of Medicine
Christie M BallantyneBaylor College of Medicine
Christie M BallantyneBaylor College of Medicine
Salim S ViraniBaylor College of Medicine
Salim S ViraniMichael E. DeBakey Veterans Affairs Medical Center
  • 1 - 6

Datasets

Release 1.2